A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
复制标题
DOI：
10.1016/j.coph.2011.07.001
复制
发表时间：
2011-10
影响因子：
4
通讯作者：
Gumbo, Tawanda
中科院分区：
文献类型：
--
作者：
Pasipanodya, Jotam G.;Gumbo, Tawanda
目前对抗结核药物耐药机制的认识是由过去60年来抗结核药物的发展历史形成的，并作为归纳概括的一部分而得出。最近，这些标准信念在受控中空纤维系统实验中得到了验证。结核分枝杆菌的耐药性与药代动力学/药效学(PK/PD)因素和药代动力学变异性等因素有关。由于我们目前的非优化给药方案导致PK/PD暴露不良，引发了一系列进化驱动的事件，首先是诱导多药外排泵，然后是染色体突变的发展，这些共同导致高水平耐药、多药耐药结核病和极端耐药结核病。
The current understanding of the mechanism of anti-tuberculosis drug resistance has been shaped by the history of development of anti-tuberculosis drugs in the past 60 years and was arrived at as part of inductive generalization. Recently, these standard beliefs have been tested in controlled hollow fiber systems experiments. Drug resistance in Mycobacterium tuberculosis was shown to be related to pharmacokinetic-pharmacodynamic (PK/PD) factors, and factors such as pharmacokinetic variability. Poor PK/PD exposures due to our current non-optimized dosing regimens initiate a chain of evolution driven events, starting with induction of multi-drug efflux pumps, followed by the development of chromosomal mutations in time, which together lead to high level resistance multi-drug resistant tuberculosis and extremely drug resistant tuberculosis.
登录
查看更多内容
影响因子：
4.9
作者：
Almeida, Deepak;Nuermberger, Eric;Grosset, Jacques
通讯作者：
Grosset, Jacques
影响因子：
4.9
作者：
Gumbo, Tawanda;Louie, Arnold;Drusano, George L.
通讯作者：
Drusano, George L.
影响因子：
4.9
作者：
Goutelle, Sylvain;Bourguignon, Laurent;Jelliffe, Roger W.
通讯作者：
Jelliffe, Roger W.
影响因子：
30.8
作者：
通讯作者：
--
DOI：
10.1164/rccm.200503-417oc
发表时间：
2006-02-01
影响因子：
24.7
作者：
Burman, W;Benator, D;El-Sadr, W
通讯作者：
El-Sadr, W